Gilead Sciences Aktie
93,06USD | 1,48USD | 1,62% |
WKN: 885823 / ISIN: US3755581036
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,90 |
The Vanguard Group, Inc. | 8,98 |
Vanguard Group, Inc. (Subfiler) | 8,80 |
Capital Research & Management Co. (World Investors) | 6,72 |
Capital Research & Management Co. (World Investors) | 6,15 |
Capital Research & Management Co. (Global Investors) | 4,96 |
State Street Corp. | 4,83 |
BlackRock Fund Advisors | 3,82 |
Vanguard Total Stock Market ETF | 3,16 |
Vanguard 500 Index Fund | 2,65 |
Dodge & Cox | 2,65 |
Wellington Management Co. LLP (Wellington Breakout) | 2,64 |
American Funds Income Fund of America | 2,50 |
BlackRock Institutional Trust Co. NA | 2,30 |
Geode Capital Management LLC | 2,21 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 11 800 | 13 600 | 14 400 | 17 000 | 18 000 |
Umsatz pro Mitarbeiter in Mio. EUR | 1,89 | 1,81 | 1,90 | 1,59 | 1,50 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 30 296 | 15 996 | 14 772 | 14 443 | 16 085 |
Summe Anlagevermögen | 31 331 | 52 411 | 53 180 | 48 728 | 46 040 |
Summe Aktiva | 61 627 | 68 407 | 67 952 | 63 171 | 62 125 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 38 977 | 50 186 | 46 888 | 41 962 | 39 376 |
Summe Eigenkapital | 22 650 | 18 221 | 21 064 | 21 209 | 22 749 |
Summe Passiva | 61 627 | 68 407 | 67 952 | 63 171 | 62 125 |
Adresse
333 Lakeside Drive, 94404 Foster City | |
Telefon | +1 (650) 574-3000 |
Fax | +1 (650) 522-5853 |
Internet | http://www.gilead.com |
Management
Adam D. Levy
Executive Director-Investor Relations |
Andrew D. Dickinson
Chief Financial Officer |
Anthony Welters
Independent Director |
Cindy Perettie
Executive Vice President-Kite |
Daniel P. O'Day
Chairman & Chief Executive Officer |
Deborah H. Telman
Secretary, EVP-Corporate Affairs & General Counsel |
Dustin Haines
Vice President & General Manager-Asia 5 |
Flavius Martin
Executive Vice President-Research |
Harish M. Manwani
Independent Director |
Jacqueline K. Barton
Independent Director |
Jacquie Ross
Head-Investor Relations |
Janet Dorling
Senior VP- Intercontinental Region |
Javier J. Rodriguez
Independent Director |
Jeffrey A. Bluestone
Independent Director |
Johanna Mercier
Chief Commercial Officer |
Joydeep Ganguly
Senior Vice President-Corporate Operations |
Jyoti K. Mehra
Executive Vice President-Human Resources |
Kelly A. Kramer
Independent Director |
Linda Slanec Higgins
Senior VP-Research & External Innovation |
Melissa Grigorieff Koomey
Vice President-Global Commercial Operations |
Merdad V. Parsey
Chief Medical Officer |
Robert D. Cook
Vice President |
Sandra J. Horning
Independent Director |
Sandra K. Patterson
SVP, Chief Accounting Officer & Controller |
Sarah C. Pope Miksinski
Executive Director-CMC Regulatory Affairs |
Stacey Y. Ma
EVP-Pharmaceutical Development & Manufacturing |
Ted W. Love
Independent Director |
Tomas Cihlar
Vice President-Virology |
William Grossman
Senior VP-Oncology Clinical Development |